Health News

Difficult-to-treat bowel cancers respond in first study of new drug combination

 1 year ago       111 Views

Dublin, Ireland: Early results from a phase I trial in a small group of patients with advanced cancer using two drugs (nivolumab and pixatimod) that stimulate the immune system report that patients with bowel cancer may benefit from the combination.

He said that the data suggested that a population of colorectal cancer patients, considered to be microsatellite stable (MSS), received benefit from the drug combination.


Author: @DailyCupofYoga

Source: eurekalert.org

Join the community!


You must be a member of healtheo360 in order to view this group

Register with Email Address

Already a member? Click here to login

healtheo360 believes strongly in user privacy.